Introduction {#s1}
============

Amino acids are the key building blocks of proteins and biomolecules and are widely exploited in different applications, from pharmaceutical chemistry and biomedicine to material science, optoelectronics and catalysis (Zhang et al., [@B58]; Mikhalevich et al., [@B34]; Solomon et al., [@B47]; López-Andarias et al., [@B31]; Raymond and Nilsson, [@B44]). The insertion of unnatural amino acids (UAAs) in peptides and peptide mimics could add specific features to these molecules, such as proteolytic stability, active functional groups and new reactivity (Clerici et al., [@B13]; Pellegrino et al., [@B39], [@B40]; Bucci et al., [@B7]). α,α disubstituted and β- homologs of natural amino acids have been particularly studied during the years for their ability to introduce conformational constrains in peptides and to stabilize specific secondary structures (Bonetti et al., [@B4]; Pellegrino et al., [@B36]; Fanelli et al., [@B16]; Kobayashi et al., [@B25]). On the other hand, γ UAAs provide a further opportunity to engineer the available backbone through the incorporation of an additional methylene group (Vasudev et al., [@B55]; Sohora et al., [@B46]). Recent studies report that γ-peptides are able to form helices, sheets and turns, whose conformational stability is increased by introducing substituents on the backbone chain (Bouillère et al., [@B5]). Moreover, cyclic γ UAAs, as gabapentin (Gpn) (Chatterjee et al., [@B11]; Konda et al., [@B26]) and γ-cyclohexyl amino acid (Guo et al., [@B19]) are able to stabilize both turn and helix conformation in oligomers and in mixed α-γ and β-γ sequences. On the other hand, the use of bicyclic γ amino acids for the stabilization of the peptide structure is much less investigated (Machetti et al., [@B32]).

In this work, we investigated the conformational behavior of both the enantiomers of the bicyclic unnatural γ amino acid 4,5,6,6a-tetrahydro-3a*H*-pyrrolo\[3,4-*d*\]isoxazole-3-carboxylic acid **1**, obtained starting from the corresponding ethyl esters recently described by us (Tamborini et al., [@B50]). Compound **1** is a conformationally constrained dipeptide analog and, in principle, it could substitute two amino acids in a peptide chain. The presence of the constrained bicyclic system could induce specific secondary structure allowing a proper orientation of the peptide arms at C- and N- termini. Furthermore, the presence of the isoxazoline ring, a core often found in biologically active compounds, could be particularly useful for future applications in the pharmaceutical field. In fact, isoxazoline derivatives are important scaffolds found in many naturally occurring and biologically active compounds possessing a wide range of bioactivities, such as antibacterial, antifungal, antiparasitic (Conti et al., [@B15]; Bruno et al., [@B6]; Pinto et al., [@B42]), anticancer (Castellano et al., [@B10]; Kaur et al., [@B23]), anti-inflammatory and anticonvulsant activity (Sperry and Wright, [@B48]; Pinto et al., [@B41], [@B43]). Isoxazolines are also considered to be important precursors for the synthesis of β-hydroxyketones (Kozikowski and Park, [@B28]; Tsantali et al., [@B53]), β-aminoalcohols (Fuller et al., [@B17]), isoxazolidines (Itoh et al., [@B22]), and many other valuable compounds. Recently, peptidomimetics containing the isoxazoline ring have been reported as β-turn mimics (Bucci et al., [@B8]; Memeo et al., [@B33]).

Starting from the (--)-(3a*S*6a*R*)-**1** and (+)-(3a*R*6a*S*)-**1** enantiomers, model peptides containing Leu-Val dipeptide at *C*-terminus and variable sequences at *N*-terminus were prepared. Their conformational behavior was investigated by NMR spectroscopy, FT-IR, circular dichroism, and molecular modeling. Our results indicated that (+)-(3a*R*6a*S*)-**1** enantiomer, in combination with glycine, is effective in stabilizing the α-turn conformation in peptides ([Figure 1](#F1){ref-type="fig"}). This structural motif occurs quite often in many key sites of proteins, such as enzyme active site, and metal binding domains (Wintjens et al., [@B57]), although few molecules are known to mimic or stabilize it on isolated peptides (Kelso et al., [@B24]; Hoang et al., [@B20]; Krishna et al., [@B29]; Wang et al., [@B56].). Our results make thus the unnatural γ-amino acid **1** of particular interest for future development of bioactive peptidomimetics.

![Natural α-turn and the proposed α-turn mimic containing the bicyclic pyrrolidine-isoxazoline γ amino acid.](fchem-07-00133-g0001){#F1}

Materials and Methods {#s2}
=====================

Materials
---------

Chemicals were obtained from Zentek (Italy) and used without further purification. Melting points were determined in a Stuart Scientific melting point apparatus in open capillary tubes and are certified. ESI mass spectra were recorded on an LCQESI. MS was recorded on a LCQ Advantage spectrometer from Thermo Finningan and a LCQ Fleet spectrometer from Thermo Scientific. CD experiments were carried out on a Jasco J-810 instrument. Spectra were obtained from 195 to 250 nm with a 0.1 nm step and 1 s collection time per step, taking three averages. The CD spectra were plotted as mean residue ellipticity θ (degree × cm^2^ × dmol^−1^) vs. wave length λ (nm). Noise-reduction was obtained using a Fourier-transform filter program from Jasco. The NMR spectroscopic experiments were carried out on a Varian OXFORD 300 MHz (300 and 75 MHz for ^1^H and ^13^C, respectively). Chemical shifts, δ, are given in ppm relative to the CHCl~3~ internal standard, and the coupling constants, *J*, are reported in hertz (Hz).

Methods
-------

### Synthesis of (--)-(3a*S*,6a*R*)-1 and (+)-(3a*R*,6a*S*)-1

Compound (**--**)-**2** or (+)-**2** (200 mg, 0.70 mmol) was dissolved in MeOH (3.0 mL) and treated with 1N NaOH aqueous solution (1.4 mL). The mixture was stirred at room temperature for 1 h and the disappearance of the starting material was monitored by TLC (Cyclohexane/EtOAc 7:3). The mixture was diluted in water (20 mL), made acidic with 2N aqueous HCl and extracted with EtOAc. The organic phase was dried over anhydrous Na~2~SO~4~ and after evaporation of the solvent, the acid derivate (--)-(3a*S*,6a*R*)**-1** or (+)-(3a*R*,6a*S*)**-1** (170 mg, 95%) was obtained as a white solid.

**(--)-(3a*S*,6a*R*)-1:** R~*f*~ (CH~2~Cl~2~/MeOH 9:1 + 1% AcOH): 0.40; \[α\]${}_{\text{D}}^{20}$: (--) 192.2 (c: 0.55 in MeOH); mp = dec. *T* \> 137°C; ^1^H NMR (300 MHz, CD~3~OD): δ 5.35 (dd, *J* = 4.8, 9.2, 1H); 4.10 (ddd, *J* = 2.2, 9.2, 9.2, 1H); 3.86--3.96 (m, 2H); 3.38--3.50 (m, 2H); 1.44 (s, 9H) ppm; ^13^C NMR (75 MHz, CD~3~OD): δ 161.28, 154.77, 152.95, 87.62, 80.33, 53.06, 50.93, 49.10, 27.12 (3C) ppm.

**HRMS** (ESI) \[M + Na\]^+^ calculated for C~11~H~16~N~2~O~5~Na: 279.0957, found: 279.0950.

**(+)-(3a*R*,6a*S*)-1:** \[α\]${}_{\text{D}}^{20}$: (+) 192.5 (c: 0.57 in MeOH).

General Procedure for Coupling Reaction
---------------------------------------

Free carboxylic acid (1 equiv.) was dissolved in CH~2~Cl~2~ (0.01M solution) and the mixture was cooled to 0°C. HOBt (1.1 equiv.) and EDC (1.1 equiv.) were added. After 1 h, free amino compound (1 equiv.) was added, followed by the addition of DIEA (2 equiv.). The reaction mixture was stirred at room temperature for 24 overnight (TLC analysis). The organic layer was washed with a 5% solution of KHSO~4~ (3 times), with a saturated solution of NaHCO~3~ (3 times) and with brine (1 time). The organic phase was dried over Na~2~SO~4~ and the solvent was removed under vacuum. The products were purified by column flash chromatography on silica gel (hexane/ethyl acetate gradient) followed by a crystallization from a mixture of ethyl acetate/hexane.

  **Product**                               **Yield (%)**   **Product**   **Yield (%)**
  ----------------------------------------- --------------- ------------- ---------------
  *N*-Boc-Leu-Val-CONH${}_{2}^{\text{a}}$   96              **8**         77
  **4**                                     65              **9**         80
  **5**                                     63              **10**        65

*see Steinke and Kula ([@B49])*.

### N-Boc-(--)-Δ^2^-isox-Leu-Val-CONH~2~ (4)

^1^H NMR (300 MHz, CDCl~3~): δ 7.11 (bs, 1H), 6.88 (d, *J* = 8.8 Hz, 1H), 6.19 (bs, 1H), 5.72 (bs, 1H), 5.34--5.29 (m, 1H), 4.56--4.48 (m, 1H), 4.31 (dd, *J* = 8.2; 6.9 Hz, 1H), 4.17--3.83 (m, 3H), 3.56 -- 3.42 (m, 2H), 2.23--2.07 (m, 1H), 1.85--1.61(m, 3H), 1.43 (s, 9H), 0.99 -- 0.92 (m, 12H) ppm.

^13^C NMR (75 MHz, CDCl~3~): δ 173.04, 171.32, 159.44, 154.28, 153.93, 87.40, 80.43, 58.24, 53.26, 52.30, 50.53, 49.32, 40.87, 30.53, 28.31, 24.82, 22.91, 21.92, 19.27, 17.93 ppm.

HRMS (ESI) \[M + Na\]^+^ calculated for C~22~H~37~N~5~O~6~Na: 490.2642, found: 490.2635.

### N-Boc- (+)-Δ^2^-isox-Leu-Val-CONH~2~ (5)

^1^H NMR (300 MHz, CDCl~3~): δ 7.05 (bs, 1H), 6.73 (d, *J* = 7.9 Hz, 1H), 6.13 (bs, 1H), 5.69 (bs, 1H), 5.37--5.28 (m, 1H), 4.56--4.47 (m, 1H), 4.36--4.27 (m, 1H), 4.18--4.07 (m, 1H), 3.99--3.77 (m, 2H), 3.61--3.41 (m, 2H), 2.28--2.10 (m, 1H), 1.78--1.57(m, 3H), 1.49 (s, 9H), 1.01 -- 0.90 (m, 12H) ppm.

^13^C NMR (75 MHz, CDCl~3~): δ 173.16, 171.54, 159.33, 154.16, 153.96, 80.34, 60.38, 58.16, 53.27, 52.25, 49.41, 41.02, 30.67, 28.32, 24.83, 22.87, 21.99, 19.20, 18.02 ppm.

HRMS (ESI) \[M + Na\]^+^ calculated for C~22~H~37~N~5~O~6~Na: 490.2642, found: 490.2635.

### NH-Boc-Phe-(-)-Δ^2^-isox-Leu-Val-CONH~2~ (8) --Mixture of two conformers-

^1^H NMR (300 MHz, CDCl~3~): δ 7.36--7.16 (m, 5H), 7.15--7.08 (m, 1H), 7.05--6.97 (m, 1H), 6.88--6.77 (m, 1H), 6.05 (bs, 1H), 5.71 (bs, 1H), 5.43 (d, *J* = 8.4 Hz 1H), 5.33--5.22 (m, 3H), 5.09--4.9 (m, 1H), 4.64--4.44 (m, 3H), 4.33--4.23 (m, 2H), 4.17--4.03 (m, 2H), 3.99--3.91 (m, 1H), 3.87--3.75(m, 2H), 3.70--3.50 (m, 2H), 3.42--3.30 (m, 1H), 3.13--3.03 (m, 1H), 2.97--2.74 (m, 3H), 2.51(dd, *J* = 12.2; 4.8 Hz, 1H), 2.21--2.05(m, 1H), 1.51--1.33 (m, 9H), 1.06 -- 0.84 (m, 12H) ppm.

^13^C NMR (75 MHz, CDCl~3~): δ 172.91, 171.38, 170.09, 159.11, 157.88, 157.30, 153.83, 152.33, 136.34, 129.46, 129.30, 128.56, 128.44, 127.12, 126.85, 96.33, 87.21, 85.98, 58.09, 53.31, 52.77, 52.36, 50.95, 49.64, 49.00, 48.59, 41.05, 40.91, 30.83, 30.62, 29.69, 28.35, 24.84, 22.81, 22.71, 19.18, 17.94 ppm.

HRMS (ESI) \[M + Na\]^+^ calculated for C~31~H~46~N~6~O~7~Na: 637.3326, found: 637.3332.

### NH-Boc-Phe-(+)-Δ^2^-isox-Leu-Val-CONH~2~ (9) --Mixture of two conformers-

^1^H NMR (300 MHz, CDCl~3~): δ 7.33--7.05 (m, 6H) 7.04--6.91 (m, 1H), 6.70 (d, *J* = 8.5 Hz, 1H), 6.13--5.91 (m, 2H), 5.46 (d, *J* = 8.5 Hz, 1H), 5.36--5.10 (m, 2H), 4.87--4.71 (m, 1H), 4.67--4.43 (m, 1H), 4.38--4.23 (m, 2H), 4.23--3.69 (m, 4H), 3.69--3.41 (m, 1H), 3.21 (dd, *J* = 14.3, *J* = 5.0 Hz, 1H), 3.10--2.79 (m, 2H), 2.54 (dd, *J* = 14.3, *J* = 5.0 Hz, 1H), 2.30--1.99 (m, 1H), 1.89--1.55 (m, 3H), 1.49 (m, 9H), 1.31 (m, 12 H) ppm.

^13^C NMR (75 MHz, CDCl~3~): δ 173.14, 172.90, 171.92, 171.23, 170.66, 170.49, 159.68, 158.86, 155.92, 155.18, 153.77. 153.59, 136.00, 129.63, 129.43, 129.15, 128.60, 128.41, 127.14, 127.05, 86.96, 85.53, 79.99, 79.88, 58.23, 57.68, 54.13, 53.47, 52.97, 52.19, 51.05, 48.82, 41.04, 40.85, 39.32, 30.88, 30.66, 28.45, 28.30, 25.05, 24.81, 22.91, 22.01, 21.51, 19.28, 17.98, 17.84 ppm.

HRMS (ESI) \[M + Na\]^+^ calculated for C~31~H~46~N~6~O~7~Na: 637.3326, found: 637.3332.

### NH-Boc-Phe-Gly-(+)-Δ^2^-isox-Leu-Val-CONH~2~ (10)

^1^H NMR (300 MHz, CD~3~CN): δ 7.47 (d, *J* = 6.9 Hz, 1H), 7.30--7.26 (m, 6H), 6.95 (d, *J* = 8.5 Hz, 1H), 6.72 (bs, 1H), 6.42 (bs, 1H), 5.63 (bs, 1H), 5.47--5.31 (m, 1H), 4.52--4.47 (m, 1H), 4.40--3.39 (m, 8H), 3.23--3.07 (m, 1H), 2.70--2.93 (m, 1H), 2.14--2.08 (m, 1H), 1.78--1.55 (m, 3H), 1.35 (s, 9H), 1.02--0.77 (m, 12H) ppm.

^13^C NMR (75 MHz, CD~3~CN): δ 173.43, 171.63, 167.09, 159.52, 154.34, 137.64, 129.27, 128.31, 126.53, 109.99, 87.41, 86.02, 79.09, 58.06, 56.82, 55.76, 53.67, 52.65, 51.39, 49.79, 48.71, 41.62, 40.43, 40.10, 37.60, 31.51, 30.55, 29.34, 27.49, 24.77, 22.27, 20.81, 18.86, 17.21, 16.63 ppm.

HRMS (ESI) \[M + Na\]^+^ calculated for C~33~H~49~N~7~O~8~Na: 694.3540, found: 694.3539.

General Procedure for *N*-Boc-Deprotection
------------------------------------------

*N*-Boc protected compound (1 equiv.) was dissolved in CH~2~Cl~2~ (0.01M) and the solution cooled at 0°C. TFA (50% v/v) was added dropwise, the solution was warmed up at room temperature and was stirred for 2 h. The solvent was removed under vacuum with the obtainment of the trifluoroacetate salt that was directly used in the next coupling step.

  **Product**                             **Yield (%)**
  --------------------------------------- ---------------
  **3**[^a^](#TN2){ref-type="table-fn"}   95
  **6**                                   95
  **7**                                   95

*see Smith and Spackman ([@B45])*.

### NH-(--)-Δ^2^-isox-Leu-Val-CONH2 (6)

^1^H NMR (300 MHz, CD~3~OD): δ 7.90 (d, *J* = 8.7 Hz, 1H), 5.53 (dd, *J* = 9.5, 4.9 Hz, 1H), 4.54 (dd, *J* = 9.8, 4.9 Hz, 1H), 4.42 (t, *J* = 8.8 Hz, 1H), 4.26 -- 4.17 (m, 1H), 3.90 -- 3.84 (m, 1H), 3.89 -- 3.75 (m, 2H), 3.58 -- 3.49 (m, 2H), 3.22 (dd, *J* = 5.9, 4.1 Hz, 1H), 2.05 (dq, *J* = 13.6, 6.8 Hz, 1H), 1.80 -- 1.59 (m, 3H), 1.05 -- 0.82 (m, 12H) ppm.

^13^C NMR (75 MHz, CD~3~OD): δ 147.47, 172.82, 159.52, 152.51, 85.48, 58.22, 52.96, 52.21, 50.55, 49.27, 40.31, 30.68, 24.54, 21.98, 20.47, 18.32, 17.08 ppm.

HRMS (ESI) \[M + Na\]^+^ calculated for C~17~H~29~N~5~O~4~Na: 390.2117, found: 390.2111.

### NH-(+)-Δ^2^-isox-Leu-Val-CONH2 (7)

^1^H NMR (300 MHz, CD~3~OD); δ 7.97 (d, *J* = 8.6 Hz, 1H), 5.53 (dd, *J* = 9.5, 4.9 Hz, 1H), 4.55 (m, 1H), 4.39 (m, 1H), 4.26 -- 4.16 (m, 1H), 3.90 -- 3.72 (m, 2H), 3.58 -- 3.43 (m, 2H), 3.24 -- 3.16 (m, 1H), 2.05 (m, 1H), 1.75 -- 1.58 (m, 3H), 1.02 -- 0.81 (m, 12H) ppm.

^13^C NMR (75 MHz, CD~3~OD): δ 147.47, 172.99, 159.40, 152.40, 128.72, 85.21, 58.05, 53.12, 52.17, 50.66, 49.14, 40.21, 30.91, 29.36, 24.84, 21.99, 20.25, 18.26, 16.90 ppm.

HRMS (ESI) \[M + Na\]^+^ calculated for C~17~H~29~N~5~O~4~Na: 390.2117, found: 390.2111.

Molecular Modeling
------------------

Compound **9** and **10** were modeled in explicit solvent with periodic boundary conditions using metadynamics and restrained molecular dynamics simulations. For each of the compounds two isomers (*cis* and *trans* with respect to the amide bond) were considered, resulting in a set of four peptides. Such molecules were solvated in a cubic box of 4 nm with chloroform (compound **8**) and acetonitrile (compound **10**) to reproduce the NMR experiment conditions. Every system has been submitted to geometry optimization with the steepest descent algorithm with a convergence of 100 kJ mol^−1^ nm^−1^. Then we performed a 1 ns equilibration in NVT conditions at 300 K, followed by a 1 ns NPT equilibration at the 1 bar and at the same temperature. After the equilibration phase, we ran a 50 ns Well Tempered Metadynamics (WTMD) with a 8.0 kJ mol^−1^ bias-factor, at a reference temperature of 300 K. To study the open and closed state of both peptides, we selected as collective variable (CV) the distance between C~β~VAL and the *N*-*tert*-butoxy carbonyl (*N*-Boc) quaternary carbon. A Gaussian hill with σ = 0.1 Å and an initial height of 1 kJ mol^−1^ was added once every 100 steps. The simulation was sped up by saving the Gaussian hills on a grid that ranged from 0 to 16 Å and spaced 0.02 Å. Compound **10** was also simulated using a 50 ns restrained molecular dynamics. Special potentials are used for imposing restraints on the motion of the system, to include knowledge from experimental data such as the NMR derived interatomic distances. Distance restraints add a penalty to the potential when the distance between specified pairs of atoms exceeds a threshold value (Abraham et al., [@B1]). The threshold values used in our simulation are reported in the [Supplementary Materials](#SM1){ref-type="supplementary-material"}.

The restraints are applied in a progressive way to give time to the peptide to relax, using a τ equal to 500 ps. Since we are using multiple distance restraints, they are not necessary satisfied at each simulation step but as a time average. The atoms restrained and the relative distances are shown in [Table S1](#SM1){ref-type="supplementary-material"}. Compound **9** and **10** have been described using the Amber99SB-ILDN Force Field (Hornak et al., [@B21]). 4,5,6,6a-Tetrahydro-3aH-pyrrolo\[3,4-*d*\]isoxazole-3-carboxylic acid residues were parameterized according to standard procedures as explained in reference (Gandini et al., [@B18]). During molecular dynamics (MD) and metadynamics simulations, temperature was held constant with the v-rescale algorithm (Bussi et al., [@B9]), while pressure was kept constant through the Berendsen barostat (Berendsen et al., [@B3]). MD simulations were performed using the leap-frog algorithm with 2 fs time-step, with holonomic constraints on every bond enforced using the LINCS algorithm. Simulations and subsequent analysis were performed with the GROMACS 5.0.4 (Van Der Spoel et al., [@B54]) program suite, while metadynamics was run along with PLUMED version 2.2.2 (Tribello et al., [@B52]).

Results and Discussion {#s3}
======================

The two enantiomers of compound **1** were obtained starting from the corresponding ethyl esters recently described by us (Tamborini et al., [@B50]). Racemate (±)-**2** (Conti et al., [@B14]) was synthesized in a flow chemistry reactor exploiting the 1,3-dipolar cycloaddition reaction of *N*-Boc-3-pyrroline with ethoxycarbonyl formonitrile oxide. An excellent enantiomeric separation (e.e. \>99%) of the racemate was achieved by semi-preparative chiral HPLC. Alkaline hydrolysis of (--)-(3a*S*6a*R*)-**2** and (+)-(3a*R*6a*S*)-**2** gave the desired (--)-(3a*S*6a*R*)-**1** and (+)-(3a*R*6a*S*)-**1**, respectively ([Scheme 1](#F8){ref-type="fig"}).

![1N NaOH, MeOH, r.t., 1h.](fchem-07-00133-g0008){#F8}

The ability of compound **1** to stabilize secondary structures was evaluated in model peptides containing ([l]{.smallcaps})-Phe at *N*-terminus and ([l]{.smallcaps})-Leu-([l]{.smallcaps})-Val sequence at *C*-terminus and ([Schemes 2](#F9){ref-type="fig"}, [3](#F10){ref-type="fig"}). This last dipeptide was chosen as it normally adopts extended conformation in solution. Compound **1** was used in both the 3a*S*6a*R* and 3a*R*6a*S* stereochemistries \[(--)-**1** and (+)-**1**, respectively\], as a different effect on peptide conformations could be expected depending on the stereochemistry of the unnatural amino acids (Pellegrino et al., [@B37]).

![Reagents and conditions: a) EDC/HOBt/DIEA, CH~2~Cl~2~ from 0°C to r.t., 24 h.](fchem-07-00133-g0009){#F9}

![Reagents and conditions: a) TFA, CH~2~Cl~2~ from 0°C to r.t, 2 h; b) EDC/HOBt/DIEA, *N*-Boc-(L)-Phe, CH~2~Cl~2~ from 0°C to r.t, 24 h; c) EDC/HOBt/DIEA, *N*-Boc-(L)-Phe-Gly-OH, CH~2~Cl~2~ from 0°C to r.t, 24 h.](fchem-07-00133-g0010){#F10}

Firstly, Leu-Val dipeptide **3** was prepared starting from ([l]{.smallcaps})-Valinamide and *NH*-Boc-([l]{.smallcaps})-Leu, according to the general coupling procedure, followed by *N*-terminus deprotection in TFA (91% overall yield). Diastereoisomeric dipeptides **4** and **5** were then achieved in good yields (65% and 63%, respectively) by a coupling reaction of (--)-**1** or (+)-**1** with dipeptide **3** ([Scheme 2](#F9){ref-type="fig"}).

Both **4** and **5** compounds were completely characterized by NMR spectroscopy (CDCl~3~, see SI for complete proton assignment). In both tripeptides, no significant Noesy effects between Leu-Val dipeptide and the scaffold were detected. Furthermore, in variable temperature experiments, the obtained Δδ/ΔT is higher than 5 ppb/K for all the amide protons, indicating the absence of H-bonds stabilizing a particular conformation. The *J*~NH−CHα~ value for NH-Val is of 8.8 Hz and 7.9 Hz, for **4** and **5**, respectively (NH-Leu appears as a broad signal for each compound). From these findings, we hypothesized that both **4** and **5** adopt an extended conformation and that the isoxazoline scaffold is not interacting with Leu-Val dipeptide.

The peptide chain was then elongated at *N*-terminus, through Boc-deprotection and coupling with ([l]{.smallcaps})-Phe. Diastereoisomeric dipeptides **8** and **9** were achieved in good overall yields (73% and 76%, respectively) ([Scheme 3](#F10){ref-type="fig"}). From NMR studies, it was found that both model peptides **8** and **9** are present as a mixture of conformers in 2:1 ratio in CDCl~3~ solution. The presence of these two conformers is probably due to the low-energy barrier *cis/trans* isomerization of the tertiary amide on the pyrrolidine as it is frequently observed on the acylated proline and in the case of tertiary cyclic amides (Laursen et al., [@B30]; Pellegrino et al., [@B38]). Regarding compound **8**, this rotation led to a splitting of the ([l]{.smallcaps})-Phe proton signals only. Furthermore, no significative Noesy effects were detected, and, in variable temperature experiments, the obtained Δδ/ΔT coefficient is high for all the amide protons. Taking all these data together, we can assume that Phe and Leu-Val dipeptide are oriented in opposite directions and that the 3a*S*6a*R* stereochemistry of the scaffold is not effective in inducing specific secondary structures when used in combination with ([l]{.smallcaps})-α-amino acids.

A different scenario was observed for compound **9**. Its two rotamers are indeed characterized by different chemical shifts, suggesting that the isomerization of the tertiary amide leads to two different structures conformations influencing the entire molecule. Unfortunately, due to several overlapping signals, it was not possible to assessing significative Noesy proximities. Variable temperature experiments were thus done, in order to investigate if the NH were involved in hydrogen bonds and, as a consequence, if the two isomers of **9** were characterized by a stable conformation in solution. In the case of the major isomer, the obtained Δδ/ΔT is around 4 ppb/K for NH-Phe, indicating that this proton could be involved in a weak/medium hydrogen bond. All the other amide protons had higher Δδ/ΔT. On the other hand, in the minor conformer the obtained Δδ/ΔT is of around 2 ppb/K for NH-Val, indicating that this proton is involved in a strong hydrogen bond. Metadynamic studies were then performed on the cis/trans tertiary amide conformers of compound **9** ([Figure 2](#F2){ref-type="fig"}).

![*Cis* and *trans* isomers of compound **9**.](fchem-07-00133-g0002){#F2}

In particular, we performed two 50 ns long metadynamics simulations, using the distance between Boc quaternary carbon and C~β~Val as collective variable (CV). This geometric parameter was selected as a suitable CV because it discriminates well between closed and extended states of the peptide. In this way, it could be possible to evaluate if the two conformers had an intrinsic tendency toward turn conformation. The *cis* isomer showed a broad free energy minimum corresponding to CV values between 5 and 8 Å, while the *trans* isomer showed much higher free energy values in this region, exhibiting a shallow minimum around 10--15 Å ([Figure 3](#F3){ref-type="fig"}).

![Potential energy as a function of distance between Boc quaternary carbon and C~β~Val obtained from Metadynamics for the two isomers of compound **9** in chloroform.](fchem-07-00133-g0003){#F3}

This different behavior could be indicative of a preference of *cis*-**9** toward a more closed conformation, although from these data it was not possible to make any further assumptions. For this reason, we envisaged that the introduction of a Gly residue between Phe and isoxazoline scaffold could increase the conformational flexibility of the *N*-terminus peptide arm favoring its interaction with the *C*-teminus part of the molecule. Compound **7** was thus elongated at *N*-terminus, through coupling with *N*-Boc-([l]{.smallcaps})-Phe-Gly-OH dipeptide using general coupling reaction conditions to obtain peptide **10** (65%, [Scheme 3](#F10){ref-type="fig"}). The NMR study on **10** (CD~3~CN, see SI for complete assignment), showed that it is present in solution as a single stable conformer (only trace amounts of a second isomer were detected). A complete set of NH~i~-NH~i+1~ Noesy proximities, whose calculated distances ranged from 2.68 to 2.96 Å, were observed ([Figure 4](#F4){ref-type="fig"} on the top right). Furthermore, long range Noesy effects involving HαGly and NHVal (3.03 Å) and HβLeu (2.73 Å) were found ([Figure 4](#F4){ref-type="fig"} on the bottom).

![Noesy proximity (red) observed for compound **10** (CD~3~CN). On the top right: zoom of the amide region. On the bottom left: Zoom of the aliphatic region. On the bottom right: zoom of the NH-aliphatic region.](fchem-07-00133-g0004){#F4}

In variable temperature experiments ([Figure 5](#F5){ref-type="fig"}), the obtained Δδ/ΔT is of around 2 ppb/K for NH-Val, while NH-Leu and one of the C-terminus amide protons possess Δδ/ΔT of around 3 and 4 ppb/K, respectively. The presence of hydrogen bonds was also confirmed by FT-IR analysis. N-H stretching bands A and B (3,500--3,000 cm^−1^region, [Figure S20](#SM1){ref-type="supplementary-material"}) are indeed downshifted as frequently observed in intramolecular hydrogen bonded conformations (Tonan and Ikawa, [@B51]; Barth, [@B2]). Furthermore, the deconvolution of the amide I band (1,700--1,600 cm^−1^) showed the presence of a band at 1,655 cm^−1^ ([Figure S20](#SM1){ref-type="supplementary-material"}), typical of α structures (Kong and Yu, [@B27]).

![Variable temperature coefficients of the amide protons (CD~3~CN).](fchem-07-00133-g0005){#F5}

In order to gain more information on the conformation of compound **10**, far-UV circular dichroism (CD) analysis in CH~3~CN (0.1 mM solution) was then performed. In [Figure 6](#F6){ref-type="fig"} the obtained CD spectrum is reported.

![CD spectrum of compound **10** in CH~3~CN (0.1 mM CH~3~CN solution).](fchem-07-00133-g0006){#F6}

It showed a maximum at around 250 nm due to the strong absorption of the isoxazoline ring, as observed by Memeo et al. ([@B33]) on similar compounds (see also the UV spectrum in the SI). In the amide bond region, two negative minima at 225 and 208 nm, with the same intensity, and a slightly positive band at 200 nm were also observed. The presence of the exciton splitting of the π → π^\*^ transition band suggested that a α-turn conformation was present (Wang et al., [@B56]), although in short peptides it is difficult to correctly evaluate the intensity of Cotton effects with respect to secondary structure motifs (Chin et al., [@B12]; Wang et al., [@B56]).

In order to completely elucidate the conformation of peptide **10**, a restrained molecular dynamic was finally performed. The restraints were based on the obtained NOESY values. When the hydrogen was not uniquely defined, like in H~α~Gly and H~β~Leu, we used the closest carbon, e.g., C~α~Gly and C~β~Leu to implement distance restrains ([Figure S3](#SM1){ref-type="supplementary-material"}). The analysis showed that C~α~Gly-C~β~Leu (A) and C~α~Gly-H~NH~Val (B) are mutually exclusive in the *trans* isomer but not in the *cis one* as shown in [Figure S1](#SM1){ref-type="supplementary-material"}. Furthermore, H-bond analysis resulted in the observation that a H-bond is between CO-Gly and NH-Val. In [Figure 7](#F7){ref-type="fig"} the most representative structure is reported.

![Compound **10** conformation during the restained MD.](fchem-07-00133-g0007){#F7}

Taking together both experimental and molecular modeling data, we can assume that, in solution, compound **10** effectively adopts a α-turn conformation. This motif is normally formed by 5 α-amino acids and is characterized by a H-bond between *i* and *i*+*4* residues. In our case, the isoxazoline scaffold replaces two of the three core amino acids ([Figure 1](#F1){ref-type="fig"}) and the H-bond is formed by the CO-Gly and NH-Val, leading to the formation of a 12 member pseudo-cycle. Furthermore, the overall structure of the peptidomimetic is reinforced by medium-weak H-bonds involving NH-Leu and one C-terminus-NH~2~, as evicted from NMR data. The presence of a α-turn conformation is also confirmed by the computational analysis of the dihedral angles of the residue i+3 and of the distances between residues i and i+4 ([Table S9](#SM1){ref-type="supplementary-material"}), as their values rely within the α-turn parameters (Pavone et al., [@B35]).

In conclusion, as α-turns are often found on biologically active sites and few molecules have been reported to mimic or stabilize them, the ability of compound (+)-**1** to stabilize α-turn conformation on isolated peptide is particularly important in view of future biological applications.
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ACN

:   Acetonitrile

Boc

:   tert-butyloxycarbonyl

DIEA, N

:   N-Diisopropylethylamine

DMF

:   Dimethylformamide

EDC

:   1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide

Gly

:   Glycine

HOBt

:   Hydroxybenzotriazole

Leu

:   Leucine

Phe

:   Phenylalanine

TFA

:   Trifluoroacetic acid

Val

:   Valine.
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